This article is more than 5 years old. Information may no longer be current.

FDA approves Mircera for treatment of anemia in pediatric patients on hemodialysis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting from another erythropoiesis-stimulating agent after their hemoglobin level was stabilized with an ESA.

According to a release from the FDA, approval was based on data from an open-label, multiple-dose, multicenter, dose-finding trial of 64 pediatric patients with chronic kidney disease on hemodialysis. Patients had stable hemoglobin (Hb) levels while previously receiving another ESA. They were administered Mircera (Vifor Pharma Inc.) intravenously once every 4 weeks for 20 weeks. After the first administration, dosage adjustments were permitted to maintain target Hb levels.

Efficacy was based on maintaining Hb levels within target levels in the clinical trial and from extrapolation from trials of Mircera in adults with CKD. The safety findings for pediatric patients were similar to those previously reported for adults, according to the release.

Reference:

www.fda.gov/drugs/informationondrugs/approveddrugs/ucm610210.htm